Recurrent Clostridium difficile infection treated with bezlotoxumab

An Pediatr (Engl Ed). 2023 Feb;98(2):141-142. doi: 10.1016/j.anpede.2022.09.010. Epub 2023 Jan 23.

Authors

Beatriz Palenzuela Afonso¹, Ana B Caparrós Nieto², Macarena González Cruz², Cristina Martínez Faci²

Affiliations

¹ Oncohematología Pediátrica, Servicio de Pediatría, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain. Electronic address: [email protected].
² Oncohematología Pediátrica, Servicio de Pediatría, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain.

PMID: 36697333
DOI: 10.1016/j.anpede.2022.09.010

No abstract available

Publication types

Case Reports

MeSH terms

Anti-Bacterial Agents* / therapeutic use
Antibodies, Monoclonal
Broadly Neutralizing Antibodies
Clostridium Infections* / drug therapy
Humans

Substances

bezlotoxumab
Broadly Neutralizing Antibodies
Anti-Bacterial Agents
Antibodies, Monoclonal